Isotechnika Pharma Inc IPHAF

RE: READ_"This Statement..Speaks Volumes"

[labumba]

also : " the Food and Drug Administration (FDA) of the United States granted fast track designation for the Company's lead drug, ISA247 under section 506 of the Federal Food, Drug and Cosmetic Act. The FDA based its decision on the following reasons: << - ISA247 is intended for the treatment of a serious or life-threatening condition, namely non-infectious posterior, intermediate and panuveitis, and - ISA247 demonstrates the potential to address medical needs unmet by available treatments for non-infectious posterior, intermediate and panuveitis. '' ------------------------------------- totally agree.....I am still confident this drug will make it to the finish line !